Business
MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting
LYON, France, June 24, 2025--MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting
About this update from Maat Pharma
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":442,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/3f5f1f12d6a6ca63432be40052c87a14"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D1ddX4VATRZDvrPnHl0Y1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTc2NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3f5f1f12d6a6ca63432be40052c87a14","width":442,"height":480}},"lazy":false},{"type":"text","content":"LYON, France, June 24, 2025--(BUSINESS WIRE)--Regulatory News:","length":62,"tagName":"p"},{"type":"text","content":"MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today presents the results of its Annual and Extraordinary General Meeting held on Friday, June 20, 2025 at 9:30 am CET at the Company's office and broadcasted live (replay available here). The quorum reached by the shareholders present, representing, or voting remotely, was above 73% of voting shares.","length":559,"tagName":"p"},{"type":"text","content":"Shareholders overwhelmingly approved most of the resolutions put forward by the Board of Directors by a majority of over 99% (with the exception of the 29th and 34th resolutions approved by nearly 69% of voters). The following resolutions were approved:","length":253,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Approval of the financial statements for fiscal year 2024;","length":58,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The compensation policy for corporate officers (Chairman, Chief Executive Officer and Directors) and the compensation paid or awarded during 2024 fiscal year – details of the votes on the said resolution is available on the Company’s website here;","length":247,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Financial resolutions, notably delegations of authority to the Board of Directors to carry out capital increases in various situations;","length":135,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Delegation of authority to the Board of Directors to decide on any merger, demerger or partial contribution of asse...